Unknown

Dataset Information

0

Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2.


ABSTRACT: INTRODUCTION:New open-angle glaucoma (OAG) and ocular hypertension (OHT) therapies that reduce treatment burden and improve outcomes relative to currently available agents are needed. Netarsudil, a novel Rho kinase inhibitor approved by the US Food and Drug Administration, reduces intraocular pressure (IOP) by increasing trabecular outflow. Two phase 3 superiority studies compared a fixed-dose combination (FDC) of netarsudil and the prostaglandin latanoprost with each active component for IOP-lowering efficacy. METHODS:Pooled efficacy and safety data were analyzed from MERCURY-1 and -2 studies in patients with OAG or OHT. Patients instilled one drop of netarsudil (0.02%)/latanoprost (0.005%) FDC (n?=?483), netarsudil (0.02%, n?=?499), or latanoprost (0.005%, n?=?486) into each eye once-daily between 20:00 and 22:00. IOP was measured at 08:00, 10:00, and 16:00 at weeks 2, 6, and the primary endpoint at month 3. RESULTS:Baseline mean diurnal IOP was 23.6, 23.6, and 23.5 mmHg in netarsudil/latanoprost FDC, netarsudil, and latanoprost groups, respectively. Mean diurnal IOP in each group was 15.3, 18.1, and 17.5 mmHg at week 2, 15.7, 18.4, and 17.4 mmHg at week 6, and 15.8, 18.4, and 17.3 mmHg at week 12. The netarsudil/latanoprost FDC met criteria for superiority compared with each active component (p?

SUBMITTER: Asrani S 

PROVIDER: S-EPMC7140751 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2.

Asrani Sanjay S   Bacharach Jason J   Holland Edward E   McKee Hayley H   Sheng Huan H   Lewis Richard A RA   Kopczynski Casey C CC   Heah Theresa T  

Advances in therapy 20200312 4


<h4>Introduction</h4>New open-angle glaucoma (OAG) and ocular hypertension (OHT) therapies that reduce treatment burden and improve outcomes relative to currently available agents are needed. Netarsudil, a novel Rho kinase inhibitor approved by the US Food and Drug Administration, reduces intraocular pressure (IOP) by increasing trabecular outflow. Two phase 3 superiority studies compared a fixed-dose combination (FDC) of netarsudil and the prostaglandin latanoprost with each active component fo  ...[more]

Similar Datasets

| S-EPMC7647436 | biostudies-literature
| S-EPMC9309311 | biostudies-literature
| S-EPMC3175210 | biostudies-literature
| S-EPMC7046276 | biostudies-literature
| S-EPMC8004483 | biostudies-literature
| S-EPMC7887148 | biostudies-literature
| S-EPMC9361429 | biostudies-literature
| S-EPMC1857560 | biostudies-literature
| S-EPMC7654727 | biostudies-literature
| S-EPMC4664487 | biostudies-other